Anti-cyclic citrullinated peptide antibodies are autoantibodies that recognize citrullinated proteins, which form through post-translational modification of arginine residues by peptidylarginine deiminase enzymes. These antibodies serve as highly specific biomarkers for rheumatoid arthritis and appear in approximately 60-70% of patients with this autoimmune condition. Anti-CCP antibodies can emerge years before clinical symptoms develop and correlate with more severe joint damage and erosive disease progression, making them valuable for early diagnosis and prognosis.
This assay operates at a detection wavelength of 450 nm and requires 50-100 μl sample volume per test. The complete assay procedure takes 1-5 hours, providing researchers with an efficient method for measuring these clinically relevant autoantibodies in human specimens.
Application Examples
Note: The following application examples are drawn from a selection of publications citing this product. For additional applications, please refer to the full list of references in the "Citations" section.
This ELISA kit has been applied in clinical research studies focused on rheumatic and autoimmune diseases, particularly for measuring anti-cyclic citrullinated peptide antibody levels in serum samples. The kit supports diagnostic profiling alongside other inflammatory and immunological markers in patient populations.
• Rheumatic disease research: Applied in studies examining rheumatoid arthritis, reactive arthritis, ankylosing spondylitis, and psoriatic arthritis through multi-laboratory collaborative research efforts
• Autoimmune disorder profiling: Used for diagnostic marker evaluation in systemic lupus erythematosus and Sjögren's syndrome patient cohorts compared to control groups
• Clinical biomarker panels: Integrated into laboratory diagnostic workflows measuring inflammatory markers, complement proteins, and immunoglobulins for rheumatology applications
• Multi-center diagnostic studies: Used across independent clinical laboratories and hospital settings for standardized autoimmune disease classification and patient categorization
